Bhindi R, et al. - In this systematic review and meta-regression of dyslipidemia therapy studies, researchers examined the link between plaque regression triggered by dyslipidemia therapies and the occurrence of major adverse cardiovascular events (MACE). They analyzed 17 prospective studies with 6,333 patients, published between 2001 and 2018 reporting death, myocardial infarction, stroke, unstable angina, or transient ischemic attack, as well as percent atheroma volume (PAV) measured by intravascular ultrasound. A 20% attenuation in the odds of MACE was found in relation to a 1% reduction in mean PAV as triggered by dyslipidemia therapies.